Ligne de temps
Jérémy Brunet
Technicien(ne)
02 avr. 2024
publication
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
Lire plus01 janv. 2022
publication
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
Lire plus02 oct. 2015
news